
    
      Patients are randomly assigned to receive lithium (Eskalith), valproate (Depakote), or
      risperidone (Risperdal) for 8 to 16 weeks. They will have weekly visits to monitor their
      response to the medication. When the study is complete, care will be transferred to the
      child's treating psychiatrist.
    
  